BioCardia Stock (NASDAQ:BCDA)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.73

52W Range

$1.96 - $23.25

50D Avg

$2.82

200D Avg

$5.14

Market Cap

$9.59M

Avg Vol (3M)

$846.76K

Beta

1.26

Div Yield

-

BCDA Company Profile


BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16

IPO Date

Nov 13, 1996

Website

BCDA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 20Dec 19
Service$183.00K$191.00K
License$500.00K$500.00K

Fiscal year ends in Dec 23 | Currency in USD

BCDA Financial Summary


Dec 23Dec 22Dec 21
Revenue$477.00K$1.35M$1.01M
Operating Income$-11.64M$-11.90M$-12.63M
Net Income$-11.57M$-11.91M$-12.62M
EBITDA$-11.23M$-11.90M$-12.56M
Basic EPS$-0.55$-0.67$-0.75
Diluted EPS$-0.55$-0.67$-0.75

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 13, 24 | 7:53 PM
Q1 24May 14, 24 | 11:00 PM
Q4 23Mar 27, 24 | 8:00 PM

Peer Comparison


TickerCompany
MLYSMineralys Therapeutics, Inc.
ABVCABVC BioPharma, Inc.
KTTAPasithea Therapeutics Corp.
AVTEAerovate Therapeutics, Inc.
ERASErasca, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
ANTXAN2 Therapeutics, Inc.
RZLTRezolute, Inc.
INDPIndaptus Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
PTIXProtagenic Therapeutics, Inc.
FBRXForte Biosciences, Inc.